Back
Top 2%
14.5%
Top 57%
10.9%
Top 8%
10.9%
Top 2%
7.7%
Top 0.8%
6.4%
Top 0.8%
5.0%
Top 0.5%
4.1%
Top 3%
3.8%
Top 67%
3.8%
Top 16%
2.8%
Top 2%
2.8%
Top 6%
1.9%
Top 1%
1.9%
Top 0.4%
1.5%
Top 5%
1.5%
Top 4%
0.9%
Top 31%
0.7%
Top 9%
0.7%
Top 7%
0.7%
Top 2%
0.7%
Top 6%
0.7%
Top 5%
0.7%
Effects of Arylsulfatase B and Pembrolizumab in Combination on Progression of Metastatic Melanoma in the B16F10 Syngeneic Mouse Model
2026-01-02
oncology
Title + abstract only
View on medRxiv
Show abstract
In this report, experiments were performed to assess how Arylsulfatase B (ARSB; N-acetylgalactosamine-4-sulfatase) treatment might interact with Pembrolizumab and improve therapeutic responses in melanoma. ARSB acts to remove 4-sulfate groups from chondroitin 4-sulfate (C4S; chondroitin sulfate A; CSA). ARSB is required for the degradation of C4S, identified as an oncofetal, tumor-agnostic antigen. Previous reports showed that in syngeneic B16F10 mouse melanomas, ARSB inhibited progression of su...
Predicted journal destinations
1
Cancers
57 training papers
2
PLOS ONE
1737 training papers
3
Nature Communications
483 training papers
4
Frontiers in Oncology
34 training papers
5
Clinical Cancer Research
22 training papers
6
British Journal of Cancer
22 training papers
7
BMC Cancer
21 training papers
8
Proceedings of the National Academy of Sciences
100 training papers
9
Scientific Reports
701 training papers
10
eLife
262 training papers
11
Cancer Medicine
17 training papers
12
Frontiers in Immunology
140 training papers
13
International Journal of Molecular Sciences
39 training papers
14
Cell Reports
25 training papers
15
iScience
74 training papers
16
Journal of Clinical Investigation
50 training papers
17
JAMA Network Open
125 training papers
18
PeerJ
46 training papers
19
Cell Reports Medicine
49 training papers
20
Aging
18 training papers
21
Diagnostics
36 training papers
22
Communications Biology
36 training papers